CDH6 Antibody-Drug Conjugate for Stable Targeted Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ovarian and renal cancers lack effective CDH6-targeting antibody-drug conjugates, limiting therapeutic options and clinical advancements.
Innovation Solution
Development of an antibody-drug conjugate with a specific structure that targets CDH6, comprising a cytotoxic drug linked via a linker to an antibody fragment with defined CDR sequences, demonstrating high specificity and stability for treating CDH6-expressing tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents are used, then broad anti-tumor coverage is achieved, but serious toxic and side effects occur due to lack of target specificity
Solution Approach 1:
The chemotherapy system is segmented into two separate components: a targeting antibody (Pc) that specifically binds to CDH6 on tumor cells, and a cytotoxic drug (D) that remains inactive until delivered to the target. This segmentation allows the toxic agent to be spatially separated from healthy tissues during administration, reducing systemic toxicity while maintaining anti-tumor efficacy through precise delivery to CDH6-expressing tumors.
Solution Approach 2:
A linker unit (L) is introduced as an intermediary component connecting the antibody and cytotoxic drug. This linker serves as a mediator that transports the toxic agent from the antibody to the tumor cell, enabling controlled release of the cytotoxic drug only at the target site. The intermediary linker prevents premature activation of the toxic agent in healthy tissues while ensuring effective delivery to the tumor.
2Measurement precision
If monoclonal antibody alone is used for tumor targeting, then target specificity is improved, but therapeutic effect is insufficient due to lack of cytotoxic capability
Solution Approach 1:
The patent merges two distinct functional components into a single conjugate system: the targeting function provided by the monoclonal antibody (Pc) that specifically binds to CDH6, and the cytotoxic function provided by the toxin molecule (D). This merging creates an integrated therapeutic agent that simultaneously achieves precise tumor targeting and potent anti-tumor killing, overcoming the limitations of using either component alone.
Solution Approach 2:
The antibody-drug conjugate represents a composite material combining a biological targeting agent (monoclonal antibody) with a chemical cytotoxic agent (camptothecin derivative). This composite structure integrates the advantages of both components: the high specificity of the antibody for CDH6-expressing tumors and the potent cell-killing capability of the cytotoxic drug, creating a therapeutically superior agent that achieves both precision and efficacy.
3Reliability
If cytotoxic drug is administered directly, then strong anti-tumor killing effect is achieved, but poor druggability and high toxicity occur
Solution Approach 1:
The cytotoxic drug is pre-connected to the antibody through a linker unit, creating a ready-to-administer conjugate where the toxic agent is already positioned for immediate delivery to the target. This preliminary assembly eliminates the need for complex co-administration protocols or in vivo activation steps, improving druggability by providing a single-step administration solution that maintains both potency and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate effectively targets and treats CDH6-expressing tumors with strong anti-tumor effects and good plasma stability, offering broad clinical application prospects for ovarian and renal cancers.
Implementation Method 1
an antibody or an antigen-binding fragment thereof that specifically binds to CDH6
Implementation Method 2
linking a monoclonal antibody specifically binding to a tumor cell surface antigen to a biologically active toxin molecule
Implementation Method 3
achieve anti-tumor effects by inhibiting topoisomerase I
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a class of antibody-drug conjugates with a novel structure. Specifically, disclosed in the present invention is an antibody-drug conjugate targeting CDH6, which has good plasma stability in plasma of mammals (such as humans or monkeys), has a relatively strong anti-tumor effect, and has wide clinical application prospects in the treatment of diseases such as tumors.